MedTrace Logo

Botulinum A Toxin in Patients With Parkinson's Disease

NCT00822913 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2009-01-15

No results posted yet for this study

Summary

The researchers investigated the effectiveness and safety of BoNT/A injected into the detrusor muscle in patients with PD and MSA all of whom had detrusor muscle overactivity unresponsive to conventional medical therapy.

Conditions

Interventions

DRUG

Intravesical injection of Botulinum A toxin

One treatment, 200 U vials diluted in 20 ml normal saline

Sponsors & Collaborators

  • University of Roma La Sapienza

    collaborator OTHER

  • University Of Perugia

    lead OTHER

Principal Investigators

  • Antonella Giannantoni, M.D. · University Of Perugia

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2008-12-31
Completion
2009-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00822913 on ClinicalTrials.gov